J
Juan P. de-Torres
Researcher at Queen's University
Publications - 93
Citations - 2573
Juan P. de-Torres is an academic researcher from Queen's University. The author has contributed to research in topics: COPD & Lung cancer. The author has an hindex of 26, co-authored 93 publications receiving 1966 citations. Previous affiliations of Juan P. de-Torres include Kingston General Hospital & University of Navarra.
Papers
More filters
Journal ArticleDOI
Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort
Borja G. Cosío,Joan B. Soriano,José Luis López-Campos,Myriam Calle-Rubio,Juan José Soler-Cataluña,Juan P. de-Torres,Jose M. Marin,Cristina Martínez-González,Pilar de Lucas,Isabel Mir,Germán Peces-Barba,Nuria Feu-Collado,Ingrid Solanes,Inmaculada Alfageme,Ciro Casanova,José Calvo Bonachera,Celia Lacárcel Bautista,Adolfo Domenech,Rosirys Guzmán,Rosa Irigaray,Meritxell López Zamora,Ángel Ríos,Rocío Córdova,Carlos Cabrera López,Alejandro Sánchez Acosta,Juan A. Gonzalez,Ramón Agüero Balbin,Eva Balcells,Elena Miguel Campos,Alicia Marin,A. Casanova,Amalia Moreno,Francisca Lourdes Márquez Pérez,Juan Antonio Riesco Miranda,Julia Tabara Rodríguez,Rafael Golpe Gómez,Javier de Miguel Díez,Francisco García Río,Salvador Díaz Lobato,Juan Bautista Galdiz Iturri,Margarita Marín Royo,Alfredo de Diego Damia +41 more
TL;DR: The proposed ACOS criteria are present in 15% of a cohort of patients with COPD and these patients show better 1-year prognosis than clinically similar patientswith COPD with no ACos criteria.
Journal ArticleDOI
COPD comorbidities network
Miguel Divo,Ciro Casanova,Jose M. Marin,Victor Pinto-Plata,Juan P. de-Torres,Javier J. Zulueta,Carlos Javier Gutiérrez Cabrera,Jorge Zagaceta,Pablo Sanchez-Salcedo,Juan Berto,Rebeca Baz Davila,Ana B. Alcaide,Claudia Cote,Bartolome R. Celli +13 more
TL;DR: A network-based analysis was applied to explore the associations between multiple comorbidities in chronic obstructive pulmonary disease patients and non-COPD controls and found there were more nodes and links in COPD compared with controls after adjusting for age, sex and number of subjects.
Journal ArticleDOI
Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data
Joan B. Soriano,Bernd Lamprecht,Ana Sofia Ramírez,Pablo Martínez-Camblor,Bernhard Kaiser,Inmaculada Alfageme,Pere Almagro,Ciro Casanova,Cristóbal Esteban,Juan José Soler-Cataluña,Juan P. de-Torres,Marc Miravitlles,Bartolome R. Celli,Jose M. Marin,Milo A. Puhan,Patricia Sobradillo,Peter Lange,Alice L. Sternberg,Judith Garcia-Aymerich,Alice M Turner,MeiLan K. Han,Arnulf Langhammer,Linda Leivseth,Per Bakke,Ane Johannessen,Nicolas Roche,Don D. Sin,Don D. Sin +27 more
TL;DR: Neither GOLD COPD classification schemes have sufficient discriminatory power to be used clinically for risk classification at the individual level to predict total mortality for 3 years of follow-up and onwards, and the prognostic accuracy of the staging documents for mortality is compared.
Journal ArticleDOI
Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer
Daniel Ajona,Maria J. Pajares,Leticia Corrales,Jose Luis Perez-Gracia,Jackeline Agorreta,Maria D. Lozano,W. Torre,Pierre P. Massion,Juan P. de-Torres,Eloisa Jantus-Lewintre,Carlos Camps,Javier J. Zulueta,Luis M. Montuenga,Ruben Pio +13 more
TL;DR: Complement fragment C4d may serve as a biomarker for early diagnosis and prognosis of lung cancer and was associated with increased lung cancer risk in asymptomatic individuals with and without lung cancer.
Journal ArticleDOI
Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.
Juan P. de-Torres,David O. Wilson,Pablo Sanchez-Salcedo,Joel L. Weissfeld,Juan Berto,Arantzazu Campo,Ana B. Alcaide,Marta García-Granero,Bartolome R. Celli,Javier J. Zulueta +9 more
TL;DR: The COPD-LUCSS is a good predictor of LC risk in patients with COPD participating in LC screening programs and validation in two different populations adds strength to the findings.